Ratings aap Implantate AG Deutsche Boerse AG

Equities

AAQ

DE0005066609

End-of-day quote Deutsche Boerse AG 06:00:00 2024-02-04 pm EST 5-day change 1st Jan Change
0.66 EUR -9.59% Intraday chart for aap Implantate AG -5.71% -10.20%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company appears to be poorly valued given its net asset value.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
-10.20% 12.23M -
-3.32% 184B
C+
-2.21% 107B
C
-4.18% 67.78B
A
+0.86% 50.66B
B-
+10.59% 47.64B
B-
+4.60% 41.12B
B+
+1.07% 26.3B
B
+1.22% 26.04B
A-
+15.06% 25.4B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes